Jyotsana Singhal was born in Agra, India, where she received her education, B.S. in 1988 and M.S. in 1990, from Agra University, Agra, India, and moved to USA in 1992. She was trained as a Lab Technician (1992 – 1995) with Prof. Bogdan Nowicki at the University of Texas Medical Branch (UTMB) at Galveston, TX, where she was promoted to Research Assistant (1996 – 1999). She joined the University of Texas at Arlington (UTA), Arlington, TX in 1999, where she was Research Associate. After that, she joined the University of North Texas Health Science Center (UNTHSC), Fort Worth, TX as Senior Research Associate in 2007, and later on she joined Beckman Research Institute of the City of Hope, National Medical Center, Duarte, CA, as Staff Scientist in 2012.
Her current research interests are in multi-drug resistance in cancer. Her research objectives and expertise are in: 1) Stress signaling and oxidative stress, 2) Carcinogenesis and chemoprevention, 3) intracellular immuno-staining and multicolor flow-cytometry, and 4) Syngeneic and xenografts model. She has published more than 50 peer-reviewed research articles in these and related areas.
Our laboratory is interested in the interface of cell signaling and oxidative stress metabolism and its role in insulin-resistance and carcinogenesis.
We are working on COH-SR4 which has shown promising anticancer and antidiabetic effects in vitro and in vivo. COH-SR4 suppresses lipogenic genes like sterol regulatory element binding protein-1c (SREBF1), acetyl-Coenzyme A carboxylase (ACOACa), peroxisome proliferator-activated receptor gamma (PPARγ), fatty acid synthase (FASN), stearoyl-Coenzyme A desaturase 1 (SCD1), carnitine palmitoyltransferase 1a (CPT1a) and 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), as well as gluconeogenic genes phosphoenolpyruvate carboxykinase 1 (PCK1) and glucose-6-phosphatase (G6PC) in the liver of obese mice. COH-SR4 inhibits cell cycle kinases, decreases vimentin and fibronectin, and activates AMPK pathway while inhibiting cancer progression. We have worked on the efficacy and mechanisms of the anticancer effects induced by 2’-hydroxyflavanone (2HF), didymin, and vicenin-2 in renal cancer, neuroblastoma and prostate cancers respectively. RLIP76 (Ral Binding Protein, RalBP1) is a 76 kDa multifunctional protein associated with carcinogenesis, metastases, drug- and radiation-resistance. We have also worked on mapping the critical upstream and downstream regulators of RLIP76 in multiple phases of tumor progression and therapeutic response.
Contribution to science